Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 18;21(1):201.
doi: 10.1186/s13063-020-4108-7.

A Randomized Controlled Trial Investigating the Effect of a Diet Low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols on the Intestinal Microbiome and Inflammation in Patients With Ulcerative Colitis: Study Protocol for a Randomized Controlled Trial

Affiliations
Free PMC article

A Randomized Controlled Trial Investigating the Effect of a Diet Low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols on the Intestinal Microbiome and Inflammation in Patients With Ulcerative Colitis: Study Protocol for a Randomized Controlled Trial

Alireza Milajerdi et al. Trials. .
Free PMC article

Abstract

Background: No conclusive treatment is available for irritable bowel disease (IBD). Adherence to a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) might alleviate clinical symptoms of IBD. However, no study has investigated the effect of low FODMAPs diet on the intestinal microbiota and inflammatory biomarkers in patients with IBD. The aim of current study is to examine the effect a low FODMAP diet on IBD symptoms, inflammation, and the intestinal microbiota in patients with ulcerative colitis.

Methods and analysis: This study is a randomized clinical trial. Thirty patients with mild to moderate ulcerative colitis will be randomly allocated to receive a low FODMAP diet (n = 15) or to continue their usual diet as control (n = 15), for 4 weeks. The quantity of intestinal microbiota including Clostridium cluster IV, Faecalibacterium prausnitzii, Rosburia spp., Lactobacillus spp., Bifidobacteria spp., Akkermansia muciniphila, Bacteroides fragilis, and Ruminococcus spp., and the Firmicutes to Bacteroidetes ratio and calprotectin and lactoferrin levels will be explored in fecal samples from patients. In addition, anthropometric measures and biochemical assessments including serum concentrations of highly sensitive-C reactive protein (hs-CRP), tumour necrosis factor-α (TNF-α) and IL-1β will be taken from patients at baseline and end of the study. The study has been registered in IRCT (IRCT20181126041763N1; registration date: 2019-01-18).

Discussion: Consumption of a low-FODMAP diet might decrease systemic and intestinal inflammation, change the bacterial population in the gut, and modulate clinical symptoms in patients with ulcerative colitis. Further studies investigating the effect of such a diet on other variables, including other bacterial species and inflammatory cytokines, are required to confirm future findings of this trial.

Keywords: FODMAP diet; Inflammation; Microbiota; RCT; Ulcerative colitis.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of study selection. BMI, body mass index
Fig. 2
Fig. 2
Flow diagram of the study process

Similar articles

See all similar articles

References

    1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627–1640. doi: 10.1016/S0140-6736(07)60750-8. - DOI - PubMed
    1. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohn’s Colitis. 2013;7(4):322–337. doi: 10.1016/j.crohns.2013.01.010. - DOI - PubMed
    1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136(4):1134–1144. doi: 10.1053/j.gastro.2009.02.038. - DOI - PubMed
    1. Rogler G, Zeitz J, Biedermann L. The search for causative environmental factors in inflammatory bowel disease. Dig Dis. 2016;34(Suppl. 1):48–55. doi: 10.1159/000447283. - DOI - PubMed
    1. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015;37(1):47-55. 10.1007/s00281-014-0454-4. - PMC - PubMed

LinkOut - more resources

Feedback